Searching...Lobbying Arrangements: Pharmacy
New Lobbying Registrations About Pharmacy By Quarter
Former Covered Federal Workers:
Other Lobbyists:
| Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
|---|---|---|---|---|---|
| Details Marketing of antiviral therapy for the H5N1 Avian Flu virus |
NeuroMolecular Pharmaceuticals
Pharmaceutical company |
BROWNSTEIN HYATT FARBER SCHRECK, P.C. | |||
| Details Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B... |
PHRMA
|
Tiber Creek Group | |||
| Details Consulting on Legislation & Public policy related to the pharmaceutical industry. |
S&B Public Solutions, LLC DBA Hilltop Public Solutions on behalf of Genentech
Pharmaceutical |
McBee Strategic Consulting, LLC | |||
| Details Pharmaceutical Manufacturing |
AstraZeneca Pharmaceuticals LP
Pharmaceutical Manufacturing |
Bryan Cave Strategies, LLC | |||
| Details Generic Issues - Biogenerics (S.1082; S.623) |
Barr Laboratories, Inc.
|
MCKENNA, LONG & ALDRIDGE | |||
| Details Legislative issues of concern to retail pharmacies, including Medicaid reimbursement provisions of H.R. 4241, Reconciliation Spending Cuts Act |
CVS/Caremark
|
in-house lobbying | |||
| Details Legislative issues of concern to retail pharmacies, including Medicaid reimbursement provisions of H.R. 4241, Reconciliation Spending Cuts Act |
CVS/Caremark
A nationwide chain of drug stores and pharmacies |
BLACKWELL SANDERS PEPER MARTIN LLP | |||
| Details Implementation of the Biologics Price Competition and Innovation Act |
Momenta Pharmaceuticals, Inc.
A biotechnology company that uses technology to develope generic and novel drugs. |
FIERCE, ISAKOWITZ & BLALOCK | |||
| Details Medicare countermeasures procurement under Project Bioshield. |
HOLLIS-EDEN PHARMACEUTICALS
Pharmaceutical company. |
Barbour Griffith & Rogers, LLC | |||
| Details FDA-related issues involving regulation of drug wholesaler-distributors |
Physician Sales & Service, Inc.
|
ALSTON & BIRD, LLP | |||
| Details NET NEUTRALITY; BROADBAND DEPLOYMENT; PRE-TEXTING |
CINGULAR WIRELESS
WIRELESS SERVICE PROVIDER |
Mattoon & Associates, LLC | |||
| Details Issues related to implementation of drug pricing and reimbursement for prescription drugs provision in Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D drug rebates; ... |
Amgen, Inc.
|
Tiber Creek Group | |||
| Details Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B... |
AstraZeneca
|
Tiber Creek Group | |||
| Details DoD TRICARE Pharmacy Program |
Express Scripts Incorporated
|
Abell, Henry & Associates, LLC | |||
| Details S1145 and HR 1908 - Patent Reform Act of 2007 - all provisions S2041 False Claims Correction Act - all provisions S3101 and HR 6331 Medicare Improvements for Patients and Providers Act of 2008 - al... |
Pharmaceutical Research and Manufacturers of America
|
Mattoon & Associates, LLC | |||
| Details outreach to HHS and DOD |
Hollis-Eden Pharmaceuticals
pharmaceutical |
O'Neill and Associates | |||
| Details H.R. 3329; End Taxpayer Funding of Gender Experimentation Act, Prohibiting the federal funding of procedures that harm children H.R.1276 / S.635; Protect Minors from Medical Malpractice Act, Ensuri... |
FAMILY RESEARCH COUNCIL
|
in-house lobbying | |||
| Details Funding for Children's Graduate Medical Education Improve Quality Standards and reporting for Children's Hospitals Medicaid reimbursement levels and procedures for Children's Hospitals |
National Association of Children's Hospitals
Advocacy for Children's Hospitals |
GRISSO CONSULTING GROUP, LLC | |||
| Details The 340B Drug Pricing Program; The Protect 340B Act; FY24 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations bill. HR 3290,to amend title III of th... |
340B Health
|
in-house lobbying | |||
| Details S. 515 - A bill to amend title 35, United States Code, to provide for patent reform. S. 610 - A bill to amend title 35, United States Code, to provide for patent reform. H.R. 1260 - To amend titl... |
Teva Pharmaceuticals USA, Inc.
|
TIMMONS AND COMPANY, INC. | |||
| Details Pricing, FDA and Medicare issues |
Genentech, Inc.
Biotechnology Research Company |
BARTLETT, BENDALL & KADESH, LLC | |||
| Details Medicaid/Medicare-Parts B&D, Patent Reform Bill, Health Reform, Patent Access, Physican Payment and Drug Prices. |
Millennium Pharmaceutical
Pharmaceutical Manufacturing |
PARRY, ROMANI, DECONCINI & SYMMS | |||
| Details IPC supports Drug Transparency in Medicaid Act (H.R. 1613) ICP supports Promoting Access to Treatments and Increasing Extremely Needed Transparent (PATIENT) Act (HR 3561) IPC supports Drug Transpa... |
Independent Pharmacy Cooperative
|
in-house lobbying | |||
| Details PDMA Compliance; FDA Rule compliance; and General Pharmaceutical Issues. |
National Coalition of Pharmaceutical Distributors
Advocacy of issues related to small and independent pharmaceutical distributors |
Mr. Matthew Simmons | |||
| Details Issues related to ESRD. Monitored implementation of drug pricing provisions related to H.R. 5376 (P.L. 117-169), The Inflation Reduction Act. Issues related to safe mobility. Issues related to rei... |
BAXTER HEALTHCARE CORPORATION
|
THE NICKLES GROUP, LLC | |||
| Details IRA implementation, 340B, biosimilars, orphan drugs, prescription drug access & reimbursement, FDA issues, transparency Medicare coverage and reimbursement issues, Medicare Part B reimbursement, tr... |
Amgen Inc.
|
TARPLIN, DOWNS & YOUNG, LLC | |||
| Details Budget/approps.- (HHS funding, health facility projects/grants); CMS - hosp. pay systems: HR3547/S1840 -Safety Net Inpat. Afford. Act - Sec. 2 - (340 Drug Discount prog.);HR1246 - Children's Hosp. ... |
Detroit Medical Center
|
in-house lobbying | |||
| Details * Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act * No Specific Bill Number. Funding for medical countermeasure enterprise including, Strategic National Stock... |
Emergent Biosolutions Inc.
|
THE OB-C GROUP, LLC | |||
| Details Pension funding requirements - Proposed legislation re this issue. |
SUPERVALU
|
THE DUBERSTEIN GROUP, INC. | |||
| Details General lobbying on pharmaceutical issues |
Amgen, Inc.
Pharmaceutical company |
King & Spalding LLP |